RegisterLogin
2025 PACC Miami | FOLFOX + Atezolizumab, Retifanlimab, Zolbetuximab, PIK3CA & Aspirin; Time to Catch-Up with Recent Advancements in the Management in Gastro-Intestinal Malignancies

2025 PACC Miami | FOLFOX + Atezolizumab, Retifanlimab, Zolbetuximab, PIK3CA & Aspirin; Time to Catch-Up with Recent Advancements in the Management in Gastro-Intestinal Malignancies

Overview

NA

Target Audience

Pharmacists

This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.

Faculty

Frank Nyanin, PharmD

Date of Release

November 23rd, 2025

Content

FOLFOX + Atezolizumab, Retifanlimab, Zolbetuximab, PIK3CA & Aspirin; Time to Catch-Up with Recent Advancements in the Management in Gastro-Intestinal Malignancies

Related Material

2025 PACC Miami | Novel Treatment in cGVHD: Axatilimab/Niktimvo

2025 PACC Miami | Novel Treatment in cGVHD: Axatilimab/Niktimvo

Pharmacology

1 Chapter

Non-CME Credit Course

2025 PACC Miami | Pharmacist Involvement in CTU Scheduling Guidelines – Interventions to Help Streamline Workflows

2025 PACC Miami | Pharmacist Involvement in CTU Scheduling Guidelines – Interventions to Help Streamline Workflows

Pharmacology

1 Chapter

Non-CME Credit Course

Explore More